Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

A simple screening process may improve mAb-based drug development

By screening potential monoclonal antibody (mAb)-based drugs solely based on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study.

3 Aug 2020

Rapid drug development yields potential treatment for yellow fever

Yellow fever, a hemorrhagic disease that is common in South America and sub-Saharan Africa, infects about 200,000 people per year and causes an estimated 30,000 deaths.

From Massachusetts Institute of Technology (MIT) 30 Jul 2020

NIH establishes clinical trial network to test vaccines and monoclonal antibodies for COVID-19

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has established a new clinical trial network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.

14 Jul 2020

Scientists discover role of surface diffusion in protein transport

Many of the most promising medicines under development are proteins, often antibodies, to help patients fight disease. These proteins must be purified as part of the manufacturing process -- a task that can be tricky and result in costly waste.

8 Jul 2020

NJIT researchers develop new efficient method to quantify therapeutic proteins

Researchers at New Jersey Institute of Technology in collaboration with Ohio University and Merck & Co. Inc. recently developed a new efficient method for targeted protein analysis -- one they say could speed up processes for disease testing, drug discovery and vaccine development.

18 Jun 2020

Researchers identify antibody cocktail with potential to neutralize SARS-CoV-2 virus

Researchers at the University of Maryland School of Medicine evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

17 Jun 2020

Cross-neutralization of SARS and COVID-19 coronaviruses by an antibody

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

19 May 2020

Study shows coronavirus does not induce cross-protective immune antibodies

According to researchers, patients infected with severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 generate antibodies that adhere to the other coronavirus; however, the cross-reactive antibodies are not actually cross-protective, as far as cell-culture experiments are concerned.

19 May 2020

Discovery Of Antibody That Blocks Infection Of SARS-Cov-2

Researchers reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells.

4 May 2020

Beta Cells From Stem Cells

The loss of insulin-secreting beta cells leads to type 1 diabetes. Islet cell transplantation has the potential to cure diabetes, but donors are rare.

28 Apr 2020

Discovery marks a critical step toward developing new anti-cancer drugs

A team of scientists led by the University of Michigan Rogel Cancer Center and Case Comprehensive Cancer Center has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.

21 Apr 2020

IL-2's flexible structure helping the immune system

Scientists have known that interleukin-2 (IL-2), a signaling molecule, strongly influences the immune system. However, attempts to leverage its potential for therapeutic purposes have went futile due to serious side effects.

From University of California Santa Cruz 18 Mar 2020